Клинико-патогенетические аспекты атеросклероза и неалкогольной жировой болезни печени
Проведен комплексный анализ научных публикаций в международных рецензируемых журналах за период 2010–2025 гг. с использованием систематического подхода к поиску, отбору и анализу работ, посвященных взаимосвязи атеросклероза и неалкогольной жировой болезни печени (НАЖБП). Атеросклероз и НАЖБП представляют собой метаболически взаимосвязанные патологические состояния, имеющие общие факторы риска и механизмы развития. НАЖБП ассоциирована с повышенным риском сердечно-сосудистых событий (ССС) независимо от традиционных факторов риска. Установлена связь между степенью выраженности стеатоза печени и прогрессированием субклинического атеросклероза. Определена ключевая роль инсулинорезистентности, дислипидемии, окислительного стресса и хронического воспаления в патогенезе обоих заболеваний. Терапевтические подходы, направленные на коррекцию метаболических нарушений, могут оказывать положительное влияние на течение обеих нозологий. Целесообразно рассматривать НАЖБП как независимый фактор риска ССС. Перспективны дальнейшие исследования, направленные на разработку комплексных стратегий лечения, учитывающих патофизиологическую взаимосвязь этих состояний.
Вишневский В.И., Снимщикова И.А., Зюзина А.А., Вишневский М.В. 2025. Клинико-патогенетические аспекты атеросклероза и неалкогольной жировой болезни печени. Актуальные проблемы медицины, 48(4): 427–442. DOI: 10.52575/2687-0940-2025-48-4-427-442. EDN: DMYFAW
Пока никто не оставил комментариев к этой публикации.
Вы можете быть первым.
Плотникова М.О., Снимщикова И.А., Вишневский В.И., Сараев И.А., Митяева Е.В., Конокотина О.А. 2024. Первичная профилактика ишемической болезни сердца: проблема, вызывающая обеспокоенность. Актуальные проблемы медицины. 47(2): 171–181. doi: 10.52575/2687-0940-2024-47-2-171-181
Adams L.A., Anstee Q.M., Tilg H., Targher G. 2017. Non-Alcoholic Fatty Liver Disease and its Relationship with Cardiovascular Disease and Other Extrahepatic Diseases. Gut. 66(6): 1138–1153. doi: 10.1136/gutjnl-2017-313884
Anstee Q.M., Darlay R., Cockell S., Meroni M., Govaere O., Tiniakos D., Burt A.D., Bedossa P., Palmer J., Liu Y.L., Aithal G.P., Allison M., Yki-Järvinen H., Vacca M., Dufour J.F., Invernizzi P., Prati D., Ekstedt M., Kechagias S., Francque S., Petta S., Bugianesi E., Clement K., Ratziu V., Schattenberg J.M., Valenti L., Day C.P., Cordell H.J., Daly A.K.; EPoS Consortium Investigators. 2020. Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically Haracterised Cohort. Journal of Hepatology. 73(3): 505–515. doi: 10.1016/j.jhep.2020.04.003
Ashraf H., Anushiravani A., Rayatpisheh M., Hamidi Alamdari D., Hossieni A., Kazeminezhad B. 2025. Association between Oxidative Stress and Liver Fibrosis Severity in Non-Alcoholic Fatty Liver Disease: Insights from the Pro-Oxidant Antioxidant Balance Method in a Population from Tehran and Mashhad, Iran. Frontiers in Medicine (Lausanne). Mar 12: 12: 1539605. doi: 10.3389/fmed.2025.1539605
Baratta F., Pastori D., Angelico F., Balla A., Paganini A.M., Cocomello N., Ferro D., Violi F., Sanyal A.J., Del Ben M. 2020. Nonalcoholic Fatty Liver Disease and Fibrosis Associated with Increased Risk of Cardiovascular Events in a Prospective Study. Clinical Gastroenterology and Hepatology. 18(10): 2324–2331.e4. doi: 10.1016/j.cgh.2019.12.026
Boursier J., Vergniol J., Guillet A., Hiriart J.B., Lannes A., Le Bail B., Michalak S., Chermak F., Bertrais S., Foucher J., Oberti F., Charbonnier M., Fouchard-Hubert I., Rousselet M.C., Calès P., de Lédinghen V. 2016. Diagnostic Accuracy and Prognostic Significance of Blood Fibrosis Tests and Liver Stiffness Measurement by FibroScan in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology. 65(3): 570–8. doi: 10.1016/j.jhep.2016.04.023
Byrne C.D., Targher G. 2020. NAFLD as a Driver of Chronic Kidney Disease. Journal of Hepatology. 72(4): 785–801. doi: 10.1016/j.jhep.2020.01.013
Cai J., Zhang X.J., Li H. 2019. The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. Hepatology. 70(3): 1026–1037. doi: 10.1002/hep.30506
Capone F., Vettor R., Schiattarella G.G. 2023. Cardiometabolic HFpEF: NASH of the Heart. Circulation. 147: 451–3. doi: 10.1161/CIRCULATIONAHA.122.062874
Choi J., Lee S.R., Choi E.K., Ahn H.J., Kwon S., Park S.H., Lee H., Chung J., Han M., Lee S-W., Han K-D., Oh S., Lip G.Y.H. 2022. Non-Alcoholic Fatty Liver Disease and the Risk of Atrial Fibrillation in Young Adults: A Nationwide Population-Based Cohort Study. Frontiers in Cardiovascular Medicine. 9: 832023. doi: 10.3389/fcvm.2022.832023
Ciornolutchii V., Ismaiel A., Bogdan J., Popa S., Surdea-Blaga T., Dumitrascu D. 2025. From Liver to Limb: Exploring the Association between Fatty Liver Disease and Peripheral Artery Disease – A Systematic Review. European Journal of Clinical Investigation. 55(10); e70075. doi: 10.1111/eci.70075
Dulai P.S., Singh S., Patel J., Soni M., Prokop L.J., Younossi Z., Sebastiani G., Ekstedt M., Hagstrom H., Nasr P., Stal P., Wong V.W., Kechagias S., Hultcrantz R., Loomba R. 2017. Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Hepatology. 65: 1557–65. doi: 10.1002/hep.29085
Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M., Zelber-Sagi S., Wai-Sun Wong V., Dufour J.F., Schattenberg J.M., Kawaguchi T., Arrese M., Valenti L., Shiha G., Tiribelli C., Yki-Järvinen H., Fan J.G., Grønbæk H., Yilmaz Y., George J. 2020. A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology. 73(1): 202–209. doi: 10.1016/j.jhep.2020.03.039
Fujii H., Kawada N. and Japan Study Group of NAFLD. 2020. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences. 21: 3863. doi: 10.3390/ijms21113863
Gong Z., Tas E., Yakar S., Muzumdar R. 2020. Hepatic Lipid Metabolism and Non-Alcoholic Fatty Liver Disease in Aging. Molecular and Cellular Endocrinology. 455: 115–130. doi: 10.1016/j.mce.2016.12.022
Hassanien M.A., Abou-El-Noeman S.A., Aboueladab E. 2014. Oxidative Stress, Antioxidant and Leptin Status in Patients with Nonalcoholic Steatohepatitis. European Journal of Academic Essays. 1(10): 17–22.
Ismaiel A., Dumitraşcu D.L. 2019. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Frontiers in Medicine. 6: 202. doi: 10.3389/fmed.2019.00202
Kasper P., Martin A., Lang S., Kütting F., Goeser T., Demir M., Steffen H.M. 2021. NAFLD and Cardiovascular Diseases: A Clinical Review. Clinical Research in Cardiology. 110(7): 921–937. https://doi.org/10.1007/s00392-020-01709-7
Labenz C., Huber Y., Michel M., Nagel M., Galle P.R., Kostev K., Schattenberg J.M. 2020. Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Digestive Diseases and Sciences. 65(7): 2112–9. doi: 10.1007/s10620-019-05986-9
Lauridsen B.K., Stender S., Kristensen T.S., Kofoed K.F., Køber L., Nordestgaard B.G., Tybjærg-Hansen A. 2018. Liver Fat Content, Non-Alcoholic Fatty Liver Disease, and Ischaemic Heart Disease: Mendelian Randomization and Meta-Analysis of 279 013 Individuals. European Heart Journal. 39(5): 385–393. doi: 10.1093/eurheartj/ehx662
Lee S.B., Park G.M., Lee J.Y., Lee B.U., Park J.H., Kim B.G., Jung S.W., Jeong I.D., Bang S.J., Shin J.W., Park N.H., Yang D.H., Kang J.W., Lim T.H., Kim H.K., Choe J., Lee H.C. 2018. Association between Non-Alcoholic Fatty Liver Disease and Subclinical Coronary Atherosclerosis: An Observational Cohort Study. Journal of Hepatology. 68(5): 1018–1024. doi: 10.1016/j.jhep.2017.12.012
Lee S.R., Han K.D., Choi E.K., Lip G.Y. 2021. Nonalcoholic Fatty Liver Disease and the Risk of Atrial Fibrillation Depending on Body Mass Index: A Nationwide Population-Based Study. Scientific Reports. 11(1): 3737. doi: 10.1038/s41598-021-83367-x
Ma W., Wu W., Wen W., Xu F., Han D., Lyu J., Huang Y. 2022. Association of NAFLD with Cardiovascular Disease and All-Cause Mortality: A Large-Scale Prospective Cohort Study Based on UK Biobank. Therapeutic Advances in Chronic Disease. 13: 20406223221122478. doi.org/10.1177/20406223221122478
Ma X., Jia J., Cui H., Zhou J., Tian F., Yang J., Zhang Y., Dai J., Cao L. 2024. Association between the Triglyceride to High Density Lipoprotein Cholesterol Ratio and the Incidence of Metabolic Dysfunction-Associated Fatty Liver Disease: A Retrospective Cohort Study. BMC Gastroenterology. Nov 1; 24(1): 389. doi: 10.1186/s12876-024-03471-w
Madan S.A., John F., Pyrsopoulos N., Pitchumoni C.S. 2020. Nonalcoholic Fatty Liver Disease and Carotid Artery Atherosclerosis in Children and Adults: A Meta-Analysis. European Journal of Gastroenterology & Hepatology. 27(11): 1237–48. doi: 10.1097/MEG.0000000000000429
Mantovani A., Petracca G., Csermely A., Beatrice G., Bonapace S., Rossi A., Tilg H., Byrne C.D., Targher G. 2022. Non-Alcoholic Fatty Liver Disease and Risk of New-Onset Heart Failure: An Updated Meta-Analysis of about 11 Million Individuals. Gut. Jul 25:gutjnl-2022-327672. doi: 10.1136/gutjnl-2022-327672
Mantovani A., Scorletti E., Mosca A., Alisi A., Byrne C.D., Targher G. 2020. Complications, Morbidity and Mortality of Nonalcoholic Fatty Liver Disease. Metabolism. 111S: 154170. doi: 10.1016/j.metabol.2020.154170
Margery A Connelly, Jonathan Velez Rivera, John R Guyton, Mohammad Shadab Siddiqui, Arun J Sanyal. 2020. Review Article: The Impact of Liver-Directed Therapies on the Atherogenic Risk Profile in Non-Alcoholic Steatohepatitis. Alimentary Pharmacology and Therapeutics. 52(4): 619–636. doi: 10.1111/apt.15935
Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A., Lingvay I., Rosenstock J., Seufert J., Warren M.L., Woo V., Hansen O., Holst A.G., Pettersson J., Vilsbøll T.; SUSTAIN-6 Investigators. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine. 375(19): 1834–44. doi: 10.1056/NEJMoa1607141
Muzurović E., Mikhailidis D.P., Mantzoros C. 2021. Non-Alcoholic Fatty Liver Disease, Insulin Resistance, Metabolic Syndrome and Their Association with Vascular Risk. Metabolism. 119: 154770. doi: 10.1016/j.metabol.2021.154770
Ndrepepa G., Colleran R., Kastrati A. 2018. Gamma-Glutamyl Transferase and the Risk of Atherosclerosis and Coronary Heart Disease. Clinica Chimica Acta: International Journal of Clinical Chemistry. 476: 130–138. doi: 10.1016/j.cca.2017.11.026
Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. 2021. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. Clinical Medicine. 10(3):467. doi: 10.3390/jcm10030467
Nobakht Motlagh Ghoochani B.F., Ghafourpour M., Abdollahi F., Tavallaie S. 2019. Pro-Oxidant Antioxidant Balance in Patients with Non-Alcoholic Fatty Liver Disease. Gastroenterology and Hepatology from Bed to Bench. 12: 124–30. doi: 10.22037/ghfbb.v12i2.1482
Nseir W., Mograbi J., Ghali M. 2012. Lipid-lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies. American Journal of Digestive Diseases. 57(7): 1773–81. doi: 10.1007/s10620-012-2118-3
Petta S., Valenti L., Bugianesi E., Targher G., Bellentani S., Bonino F. 2016. A "Systems Medicine" Approach to the Study of Non-Alcoholic Fatty Liver Disease. Digestive and Liver Disease. 48(3): 333–42. doi: 10.1016/j.dld.2015.10.027
Pouwels S., Sakran N., Graham Y., Leal A., Pintar T., Yang W., Kassir R., Singhal R., Mahawar K., Ramnarain D. 2022. Non-Alcoholic Fatty Liver Disease (NAFLD): A Review of Pathophysiology, Clinical Management and Effects of Weight Loss. BioMed Central Endocrine Disorders. Endocrine Disorders. 22(1): 63. doi: 10.1186/s12902-022-00980-1
Qu B., Qu T. 2015. Causes of Changes in Carotid Intima-Media Thickness: A Literature Review. Cardiovascular Ultrasound. 13: 46. doi: org/10.1186/s12947-015-0041-4
Ro J. H., Lee J. H., Lee H., Yun Y. H., Kim M., Kim Y. G. et al. 2020. The Relationship between Non-Alcoholic Fatty Liver Disease and the Risk of Atrial Fibrillation in Healthy Adults. Liver International. 40(2): 338–46. doi: 10.1111/liv.14236
Simon T.G., Roelstraete B., Khalili H., Hagström H., Ludvigsson J.F. 2021. Mortality in Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: Results from a Nationwide Cohort. Gut. 70(7): 1375–1382. doi: 10.1136/gutjnl-2020-322786
Snimshchikova I.A., Plotnikova M.O., Kulakova A.S. 2024. New Horizons in the Study of WNT and JAK/STAT Signaling Pathways in Cardiometabolic Diseases. The Open Biomarkers Journal. 14; e18753 183297843
Stefan N., Häring H.U., Cusi K. 2019. Non-Alcoholic Fatty Liver Disease: Causes, Diagnosis, Cardiometabolic Consequences, and Treatment Strategies. Lancet Diabetes Endocrinol. 7(4): 313–24. doi: 10.1016/S2213-8587(18)30154-2
Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. 2016. Non-Alcoholic Fatty Liver Disease and Risk of Incident Cardiovascular Disease: A Meta-Analysis. Journal of Hepatology. 65(3): 589–600. doi: 10.1016/j.jhep.2016.05.013
Targher G., Byrne C.D., Tilg H. 2020. NAFLD and Increased Risk of Cardiovascular Disease: Clinical Associations, Pathophysiological Mechanisms and Pharmacological Implications. Gut. 9: 1691–1705. doi: 10.1136/gutjnl-2020-320622
Taylor R.S., Taylor R.J., Bayliss S., Hagström H., Nasr P., Schattenberg J.M., Ishigami M., Toyoda H., Wai-Sun Wong V., Peleg N., Shlomai A., Sebastiani G., Seko Y., Bhala N., Younossi Z.M., Anstee Q.M., McPherson S., Newsome P.N. 2020. Association between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 158(6): 1611–1625.e12. doi: 10.1053/j.gastro.2020.01.043
Vilar-Gomez E., Calzadilla-Bertot L., Wai-Sun Wong V., Castellanos M., Aller-de la Fuente R., Metwally M., Eslam M., Gonzalez-Fabian L., Alvarez-Quiñones Sanz M., Conde-Martin A.F., De Boer B., McLeod D., Hung Chan A.W., Chalasani N., George J., Adams L.A., Romero-Gomez M. 2018. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients with Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 155: 443–57. doi: 10.1053/j.gastro.2018.04.034
Xia G., Xu Y., Zhang C., Li M., Li H., Chen C. 2024. High Levels of Serum Hypersensitive C-Reactive Protein are Associated with Non-Alcoholic Fatty Liver Disease in Non-Obese People: A Cross-Sectional Study. European Journal of Medical Research. 29: 496. doi: org/10.1186/s40001-024-02065-2
Xu T., Li S., Wu S., Zhang S., Wang X. 2024. Non-Alcoholic Fatty Liver Disease: A New Predictor of Recurrent Ischemic Stroke and Transient Ischemic Attack in Patients with Carotid Atherosclerosis. European Journal of Radiology. 181: 111754. doi: 10.1016/j.ejrad.2024.111754
Ying M., Yu W., Qin W., Nanwei T. 2025. The Fibrosis-4 Index and its Association with Carotid Atherosclerosis in type 2 Diabetes: A Cross-Sectional Study in China. BMC Cardiovascular Disorders. 25(1): 35. doi: 10.1186/s12872-025-04491-4
Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Devins T., Johansen O.E., Woerle H.J., Broedl U.C., Inzucchi S.E., or the EMPA-REG OUTCOME Investigators. 2015. Empagliflozin, Cardiovascular Outcomes and Mortality in type 2 Diabetes. The New England Journal of Medicine. 373: 2117–28. doi: 10.1056/NEJMoa1504720
Zou B., Yeo Y.H., Cheung R., Ingelsson E., Nguyen M.H. 2021. Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. Digestive Diseases and Sciences. 66(6): 2092–100. doi: 10.1007/s10620-021-06954-y
Работа выполнена в ОГУ имени И.С. Тургенева в рамках государственного задания № 075-00195-25-00 на 2025 год и на плановый период 2026 и 2027 годов, проект FSGN-2024-0014 (1024041900023-6-3.1.3; 3.2.12; 3.2.4).